News

Avicanna’s Q2 2025 results reveal a company navigating a complex cannabis market, demonstrating both progress and persistent challenges. While...

Evaxion A/S, a clinical-stage AI-driven vaccine developer, announced its second-quarter 2025 financial results, highlighting key pipeline advancements and strategic...

Lexeo Therapeutics’ recent business updates reveal a company aggressively pursuing growth and solidifying its position in the genetic medicine...

Cassava Sciences is pivoting to Tuberous Sclerosis Complex (TSC)-related epilepsy, announcing positive preclinical data for its simufilam therapy and...

Abeona Therapeutics has launched Zevaskyn, the first and only gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds, marking...

Medipharm Labs Corp., a pharmaceutical company specializing in precision-based cannabinoids, reported a 14% year-over-year revenue increase to $11.8 million...

MediWound’s Q2 2025 results showcase a company navigating the complex landscape of advanced wound care therapeutics, balancing ongoing commercialization...

Atai Life Sciences’ planned merger with Beckley Psytech, alongside positive Phase 2b trial data for its intranasal mebufotenin benzoate...

Shattuck Labs has submitted an Investigational New Drug (IND) application for SL-325, its lead Death Receptor 3 (DR3) blocking...

Eledon Pharmaceuticals’ recent Q2 2025 update reveals encouraging progress for its lead candidate, tegoprubart, an anti-CD40L antibody, in the...